Valuation
- Market cap
- 124,000
- Revenue TTM
- $0
- Net income TTM
- $-1,950,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.02
Trading
- Volume
- 5,200
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 1,241,106,000
- Stochastic %K
- —
- Beta
- 1.37
- Analysts
- Strong Sell
- Price target
- $0.01
Company profile
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New Yo...
Show more
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 509 531 1671
- Website
- https://www.globestartherapeutics.com
- Address
- 1280 Lexington Avenue, Suite 1290 FRNT 2, New York, United States
Latest news
No headlines yet.
